#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Martin Schwill Email
Scientist Personalized Medicine . TOLREMO Therapeutics
Muttenz,
LocationPrimary Email
How to contact Martin Schwill
Join and see Martin's contact info for free!Current Roles
Employees:
11Revenue:
$2.2MAbout
TOLREMO therapeutics AG (“TOLREMOâ€) is a Swiss biotechnology company that was spun out of ETH Zurich in 2017. Based on cutting-edge science and guided by pioneering real-world medicine, TOLREMO created a broad cancer drug resistance platform that provides a unique entry point into a major clinical problem. In two parallel R&D programs the company develops resistance-breaking add-on therapies that extend the therapeutic benefit of oncogene-targeting cancer drugs (Adaptive Drug Resistance Program) and anti-angiogenic cancer drugs (Hypoxia-Driven Drug Resistance Program). TOLREMO's unique drug resistance platform has the potential to catalyze a new wave of potent resistance-breaking molecules that will meaningfully extend the lives of patients suffering from cancer. To learn more visit www.tolremo.com. TOLREMO is headquartered on the ETH Hönggerberg campus in Zurich, Switzerland, where the company is part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs and cutting-edge technology platforms. TOLREMO enjoys broad access to state-of-the art ETH infrastructure including laboratory space and an industry standard robotic screening facility.TOLREMO Therapeutics Address
Hofackerstrasse 40bMuttenz, null